Patents by Inventor Matthew Perry

Matthew Perry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7239656
    Abstract: A method of minimizing contamination of optical components of a laser resonator is disclosed. The resonator components are located in an enclosure, which may contain contaminants including water vapor and organic favor released by the optical components, mounts of the optical components, or the enclosure itself. The enclosure may also contain suspended particulate matter. In order to reduce the level of these contaminants, a purging system extracts gas from the enclosure and passes the gas through a desiccant, an organic vapor trapping material, and a particulate matter filter then returns the extracted gas to the enclosure. The purging system is particularly useful for ultrafast lasers and ultraviolet lasers where the power of the laser radiation increases the probability of destabilizing reactions between laser radiation and contaminants.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: July 3, 2007
    Assignee: Coherent, Inc.
    Inventors: Yang Pang, Matthew Perry Philpott
  • Publication number: 20070076738
    Abstract: A system, method, and computer-readable medium for resource migration in a distributed telecommunication system is provided. Respective sets of performance parameters of a first plurality of nodes disposed in a first node group and a second plurality of nodes in a second node group are collected. Service capabilities of the first node group and the second node group are evaluated based on the sets of performance parameters. One node group of the first node group and the second node group is designated as a currently preferred node group in response to evaluation of the service capabilities. The steps of collecting, evaluating, and designating are repeated a plurality of times. The currently preferred node group is designated as an active preferred node group in the event that a sequence of evaluating service capabilities each results in the one node group being designated as the currently preferred node group.
    Type: Application
    Filed: October 3, 2005
    Publication date: April 5, 2007
    Applicant: Santera Systems, Inc.
    Inventors: James Ludwig, Matthew Perry, Lawrence Dillard
  • Publication number: 20070032523
    Abstract: The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: March 30, 2004
    Publication date: February 8, 2007
    Inventors: Moya Caffrey, Christopher Luckhurst, Tobias Mochel, Matthew Perry, Brian Springthorpe
  • Publication number: 20060281726
    Abstract: The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: March 23, 2004
    Publication date: December 14, 2006
    Inventors: Christopher Luckhurst, Matthew Perry, Brian Springthorpe
  • Publication number: 20060264463
    Abstract: The present invention provides a compound of a formula (1): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: May 6, 2004
    Publication date: November 23, 2006
    Inventors: Christopher Luckhurst, Tobias Mochel, Matthew Perry, Brian Springthorpe, Linda Stein
  • Publication number: 20060040984
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: September 12, 2003
    Publication date: February 23, 2006
    Inventors: Christopher Luckhurst, Matthew Perry, Brian Springthorpe
  • Patent number: 6984644
    Abstract: The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: January 10, 2006
    Assignee: AstraZeneca AB
    Inventors: David Cheshire, Andrew Cooke, Martin Cooper, David Donald, Mark Furber, Matthew Perry, Philip Thorne
  • Patent number: 6971995
    Abstract: A method for splinting rib injuries is disclosed. A pair of anchor strips having a plurality of fasteners on their exposed surfaces are attached to the skin of the chest cavity by an adhesive, the strips being more or less vertically oriented and equidistantly spaced from the injury. Elastomeric straps having a plurality of fastener receivers are removably fastened to the anchor strips across the injury so as to produce a stabilizing/reducing force at the injury. Tension in the straps and orientation of the straps are adjusted to maximize patient comfort. In another embodiment a pad is placed between the elastomeric straps and the chest wall. In other embodiments the pad is a hot or cold compress. In yet another embodiment the pad is connected to a cold therapy machine.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: December 6, 2005
    Inventors: Michael Alan Rolnick, Matthew Perry Warden, Robert Allen Van Wyk
  • Publication number: 20050250792
    Abstract: The invention provides compounds of formula (I): wherein R1, R2, R3, R6, Z, Q, m, n, X1, X2, X3, X4 and T are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions.
    Type: Application
    Filed: March 16, 2005
    Publication date: November 10, 2005
    Inventors: Stephen Thom, Andrew Baxter, Nicholas Kindor, Thomas McInally, Brian Springthorpe, Matthew Perry, David Harden, Richard Evans, David Marriott
  • Patent number: 6958350
    Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, R4, R5, N, X and Y are as defined in the specification, processes, for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions.
    Type: Grant
    Filed: February 18, 2002
    Date of Patent: October 25, 2005
    Assignee: AstraZeneca AB
    Inventors: Stephen Brough, Thomas McInally, Matthew Perry, Brian Springthorpe
  • Publication number: 20050187500
    Abstract: A compression treatment system is provided that includes a first bladder supported about a limb. A second bladder is supported about the limb. The bladders are in fluid communication with a fluid source and the bladders are inflated such that the first bladder is inflated for a first time period and the second bladder is inflated for a second time period. The second time period is initiated within the first time period. A single pressure sensor communicates with the first bladder and the second bladder.
    Type: Application
    Filed: February 23, 2004
    Publication date: August 25, 2005
    Inventors: Matthew Perry, Mark Vess, Scott Wudyka
  • Publication number: 20050176708
    Abstract: The present invention provides a compound of formula (I), wherein: Z is (A:) OR (B) and wherein the remaining variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of achemokine (such as CCR3) or H1 mediated disease state,
    Type: Application
    Filed: March 17, 2003
    Publication date: August 11, 2005
    Inventors: Christopher Luckhurst, Matthew Perry, Hitesh Sanganee, Brian Springthorpe
  • Patent number: 6903085
    Abstract: The invention provides compounds of formula (I) wherein R1, R2, R3, R6, Z, Q, m, n, X1, X2, X3, X4 and T are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: June 7, 2005
    Assignee: AstraZeneca, AB
    Inventors: Stephen Thom, Andrew Baxter, Nicholas Kindor, Thomas McInally, Brian Springthorpe, Matthew Perry, David Harden, Richard Evans, David Marriott
  • Publication number: 20040235894
    Abstract: The invention provides a compound of formula (I), wherein: T is C(O) or S(O)2; W is C(O) or S(O)2; X is CH2, O or NH; Y is CR5 or N; R1 is optionally substituted aryl or optionally substituted heterocyclyl; R2 is hydrogen or C1-6alkyl; R3 is hydrogen or optionally substituted C1-6alkyl; and R4 is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; that are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis.
    Type: Application
    Filed: December 12, 2003
    Publication date: November 25, 2004
    Inventors: Richard Evans, Matthew Perry, Brian Springthorpe
  • Patent number: 6798813
    Abstract: A method of minimizing contamination of optical components of a laser resonator is disclosed. The resonator components are located in an enclosure, which may contain contaminants including water vapor and organic favor released by the optical components, mounts of the optical components, or the enclosure itself. The enclosure may also contain suspended particulate matter. In order to reduce the level of these contaminants, a purging system extracts gas from the enclosure and passes the gas through a desiccant, an organic vapor trapping material, and a particulate matter filter then returns the extracted gas to the enclosure. The purging system is particularly useful for ultrafast lasers and ultraviolet lasers where the power of the laser radiation increases the probability of destabilizing reactions between laser radiation and contaminants.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: September 28, 2004
    Assignee: Coherent, Inc.
    Inventors: Yang Pang, Matthew Perry Philpott
  • Publication number: 20040176411
    Abstract: The invention provides compounds of formula (I):[Chemical formula should be inserted here. Please see paper copy] wherein: T is C(O) or S(O)2; W is C(O) or S(O)2; X is CH2, O or NH; Y is CR11 or N; n is 0, 1 or 2; m is 1 or, when Y is CR11 m is 0; R1 is optionally substituted aryl or optionally substituted heterocyclyl; R2, R3, R,4, R5, R6, R7 and R8 are, independently, hydrogen or C?1-6#191 alkyl; R9 is hydrogen or C1-C6 alkyl; R10 is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; and R11 is hydrogen or C1-C6 allkyl; that are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis.
    Type: Application
    Filed: January 8, 2004
    Publication date: September 9, 2004
    Inventors: Richard Evans, Matthew Perry, Brian Springthorpe
  • Patent number: 6770646
    Abstract: The invention provides certain pyrrolo-, thieno-, furano-and pyrazolo-[3,4-d]-pyridazinones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: August 3, 2004
    Assignee: AstraZeneca AB
    Inventors: John Bantick, Martin Cooper, Philip Thorne, Matthew Perry
  • Publication number: 20040102483
    Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, R4, R5, N, X and Y are as defined in the specification, processes, for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions.
    Type: Application
    Filed: August 18, 2003
    Publication date: May 27, 2004
    Inventors: Stephen Brough, Thomas Mcinally, Matthew Perry, Brian Springthorpe
  • Publication number: 20040014634
    Abstract: The invention provides thieno[2,3-d]pyrimidinediones of general formula (I), wherein R, R1, R2 and R3 are as defined in the specification, processes for their production, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: June 27, 2003
    Publication date: January 22, 2004
    Inventors: John Bantick, Anthony Ingall, Matthew Perry, Rachel Reynolds
  • Publication number: 20030191142
    Abstract: The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.
    Type: Application
    Filed: October 7, 2002
    Publication date: October 9, 2003
    Applicant: AstraZeneca AB
    Inventors: David Cheshire, Andrew Cooke, Martin Cooper, David Donald, Mark Furber, Matthew Perry, Philip Thorne